The appropriate duration of beta-blocker treatment after a heart attack (a myocardial infarction [MI]) is unknown in patients who do not need to take beta-blockers for another reason. In the ABYSS ...
Long-term oral Beta-blocker therapy, including bisoprolol, metoprolol, and carvedilol, reduces the composite endpoint of all-cause death, new myocardial infarction, or heart failure by 25% ...
Biogen Idec (BIIB) and PDL BioPharma (PDLI) announce that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium-enhancing lesions when daclizumab is added to interferon beta ...
Funding will accelerate development of manufactured pancreatic beta cells capable of restoring insulin production using Syntax’s Cellgorithm™ technology Syntax Bio, a synthetic biology company ...
MedPage Today on MSN
Gene Therapy Shows Signs of Delayed Progression in Fatal Neurodegenerative Disease
All participants had adverse events, but most were moderate in severity ...
The cardiovascular safety of an interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction (MI) and there was no benefit to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results